A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer.

作者
Constantine Alifrangis,David Shipway,Ondřej Gojiš,Marie A. Emson,Diane Mackie,R. Charles Coombes,Carlo Palmieri
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:28 (15_suppl): 1097-1097
标识
DOI:10.1200/jco.2010.28.15_suppl.1097
摘要

1097 Background: Docetaxel and vinorelbine as single agents have both demonstrated efficacy in the treatment of metastatic breast cancer. This prospective study compared the efficacy of these two treatments in anthracycline refractory metastatic breast cancer, and assessed the disease response when used in cross over after disease progression on the initial regime. Methods: Patients with metastatic breast cancer who had progressed following anthracycline treatment were randomly assigned to either docetaxel 100mg/m2 on day 1 every 21 days or vinorelbine 25mg/m2 day 1 every 14 days. Patients were eligible to switch over to the other regime at progression. Results: 38 patients were randomized, 18 to docetaxel and 20 to vinorelbine, 4 patients became ineligible as a result of protocol violations or withdraw from study (1 in docetaxel, 3 in vinorelbine), and response data was not available on 1 patient randomized into docetaxel arms. The objective response was 12.5% (PR) in the docetaxel arm with 31% obtaining clinical benefit from stable disease (SD). In the vinorelbine arm there was a 6% PR with 6% SD. The median time to progression was 10.8 weeks (range 3-39 weeks) in the docetaxel arm and 9.5 weeks (range 4-37 weeks) in the vinorelbine arm. At progression 37.5% (6 patients) switched from docetaxel (T) to vinorelbine (V) and 53% (9 patients) from vinorelbine (V) to docetaxel (T). There was 1 objective response in V→T but none in T→V. The median time to progression was 9.5 weeks (2-16 weeks) in T→V and 15 weeks (range 7-43 weeks) in V→T. Grade 3 or 4 haematological toxicities were more common in the docetaxel arm (11) compared to the vinorelbine arm (1). Conclusions: Docetaxel and vinorelbine have similar efficacy as single agents in anthracycline refractory disease, however vinorelbine is better tolerated. Whilst an objective response was seen only in the crossover of V→T, clinical benefit was observed in both V→ T and T→V crossover. No significant financial relationships to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AISIR发布了新的文献求助10
刚刚
sskaze发布了新的文献求助10
刚刚
刚刚
洁净的钢笔完成签到,获得积分10
刚刚
1秒前
zhikaiyici发布了新的文献求助30
1秒前
2秒前
我是老大的应助被尘南浔采纳,获得10
2秒前
热心万天发布了新的文献求助10
2秒前
3秒前
3秒前
打打的应助被拓跋涵易采纳,获得10
3秒前
有病早治完成签到 ,获得积分10
4秒前
汉堡包的应助被liyu采纳,获得10
4秒前
freshme完成签到,获得积分10
5秒前
科研通AI6.2的应助被叶林海采纳,获得10
5秒前
5秒前
青衣完成签到,获得积分10
6秒前
Ava的应助被shenxian82133采纳,获得10
7秒前
wyy发布了新的文献求助10
7秒前
强强发布了新的文献求助10
7秒前
111发布了新的文献求助10
8秒前
昔年完成签到 ,获得积分10
9秒前
Owen的应助被LUXURY采纳,获得10
9秒前
阿阿阿Q完成签到,获得积分10
10秒前
10秒前
充电宝的应助被zhikaiyici采纳,获得30
10秒前
11秒前
缓慢的秋莲完成签到,获得积分10
11秒前
YD发布了新的文献求助10
11秒前
13秒前
gwf971021完成签到,获得积分10
13秒前
sskaze完成签到,获得积分10
13秒前
14秒前
科目三的应助被fyj采纳,获得10
14秒前
上官老黑完成签到 ,获得积分10
15秒前
ovo完成签到 ,获得积分10
15秒前
周一发布了新的文献求助10
16秒前
paper_king发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193